Founded in 2008, Alteogen is a leading bio venture company whose portfolio includes next-generation Bio-better, with improved efficacy in comparison with existing biologics and biosimilars that demonstrate “comparability” to the existing biologics with proprietary platform technology.

Alteogen focus on the cutting edge areas of the industry, long-acting bio-betters, proprietary antibody-drug conjugate, Hybrozyme™, and monoclonal antibody biosimilars.
Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting bio-better technology on its own, NexMab™ ADC Technology, an Antibody-Drug Conjugate technology, novel human hyaluronidase PH 20 variant based on Hybrozyme™ Technology and is jointly developing monoclonal antibody Biosimilars with overseas strategic alliance partners.